Track VistaGen Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

VistaGen Therapeutics, Inc. VTGN Open VistaGen Therapeutics, Inc. in new tab

0.6017 USD
EPS
-1.90
P/B
0.49
ROE
-101.55
Beta
0.30
Target Price
0.97 USD
VistaGen Therapeutics, Inc. logo

VistaGen Therapeutics, Inc.

🧾 Earnings Recap – Q3 2026

Vistagen Therapeutics reported significant progress in its clinical-stage programs, highlighted by the completion of the PALISADE-3 Phase III trial and continued advancements in its women's health product candidate, refisolone.

  • Completed the randomized portion of the PALISADE-3 Phase III trial focused on social anxiety disorder, with ongoing enhancements for the PALISADE-4 trial.
  • Received USAN adoption for refisolone, a hormone-free treatment candidate for menopause-related symptoms, with an IND submission planned for H1 2026.
  • Cash position stands at $61.8 million, supported by company-wide cash preservation measures to ensure operational efficiency and strategic flexibility.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateJune 16, 2026
EPS-1.90
Book Value1.29
Price to Book0.49
Debt/Equity2.80
% Insiders0.268%
Growth
Revenue Growth0.30%
Estimates
Forward P/E-0.55
Forward EPS-1.13
Target Mean Price0.97

DCF Valuation

Tweak assumptions to recompute fair value for VistaGen Therapeutics, Inc. (VTGN)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

VistaGen Therapeutics, Inc. Logo VistaGen Therapeutics, Inc. Analysis (VTGN)

United States Health Care Official Website Stock

Is VistaGen Therapeutics, Inc. a good investment? VistaGen Therapeutics, Inc. (VTGN) is currently trading at 0.6017 USD. Market analysts have a consensus price target of 0.97 USD. This suggests a potential upside from current levels.

Earnings Schedule: VistaGen Therapeutics, Inc. is expected to release its next earnings report on June 16, 2026. The market consensus estimate for Forward EPS is -1.13.

Investor FAQ

Does VistaGen Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is VistaGen Therapeutics, Inc.?

VistaGen Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be June 16, 2026. The company currently has a trailing EPS of -1.90.

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Exchange Ticker
NCM (Australia) VTGN
NMS (United States) SIEN

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
Aug. 14, 2014 0.050000
June 7, 2023 0.030000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion